Name
Purdue University Globle
NU576 NP II – Primary Care of Women’s Health
Prof. Name
Date
Perimenopause, menopause, hormone therapy, infertility evaluation, and gynecologic disorders are important topics in advanced nursing practice. Perimenopause is the transition leading to menopause, while menopause marks the permanent cessation of menstruation after 12 consecutive months without a menstrual period. Hormone therapy can effectively manage bothersome menopausal symptoms, but treatment should be individualized according to the patient’s medical history, age, symptoms, and risks. Infertility evaluation focuses on ovulation, reproductive anatomy, and other factors that may affect conception.
This NU576 Unit 3 quiz study guide reviews essential reproductive health concepts, including menopausal symptoms, hormone replacement therapy, genitourinary syndrome of menopause, osteoporosis prevention, amenorrhea, dysmenorrhea, and infertility testing. It is designed to support nursing students preparing for assessments and strengthen clinical reasoning for advanced practice nursing.
Perimenopause is the reproductive transition that occurs before menopause. During this stage, ovarian hormone production becomes less predictable, ovulation may become irregular, and menstrual cycles often change. The transition commonly begins during the mid-to-late 40s, although the timing varies. Some women experience symptoms earlier, and early menstrual changes should not automatically be attributed to perimenopause.
Menopause is diagnosed retrospectively after 12 consecutive months without menstruation when there is no other obvious cause. The average age of natural menopause is approximately 51 years. Menopause is a normal biological process rather than a disease, although its symptoms may significantly affect sleep, work, relationships, and quality of life.
Pregnancy remains possible during perimenopause because ovulation may still occur. Women who do not wish to become pregnant should continue using appropriate contraception until menopause is confirmed according to clinical guidance.
Hormonal fluctuations during the menopausal transition may cause a variety of physical and emotional changes. Common symptoms include:
Hot flashes and night sweats.
Irregular or unpredictable menstrual cycles.
Changes in menstrual flow and cycle length.
Sleep disturbances.
Mood changes and irritability.
Vaginal dryness and discomfort.
Changes in sexual desire.
Difficulty concentrating or a feeling of mental fog.
Hot flashes, also called vasomotor symptoms, are among the most common complaints associated with menopause. Their severity and duration vary considerably between individuals.
Menopause hormone therapy (HT), also called menopausal hormone therapy, is one of the most effective treatments for bothersome vasomotor symptoms such as hot flashes and night sweats. It may also be used to treat genitourinary symptoms and help prevent bone loss in appropriately selected patients.
Treatment decisions should be based on symptom severity, age, time since menopause, medical history, and personal preferences. Hormone therapy is not automatically appropriate for every woman, and clinicians should review both potential benefits and risks before prescribing.
For suitable patients, hormone therapy may provide the following benefits:
Reduces moderate to severe hot flashes and night sweats.
Improves sleep and quality of life when symptoms are related to menopause.
Treats vaginal dryness and other genitourinary symptoms.
Helps prevent bone loss and reduces fracture risk while therapy is used.
May support sexual comfort when vaginal symptoms are contributing to discomfort.
The choice between systemic and local treatment depends on the patient’s symptoms. Systemic estrogen reaches the bloodstream and is commonly used for vasomotor symptoms. Low-dose vaginal estrogen is primarily used for localized genitourinary symptoms.
Women who have an intact uterus generally need a progestogen when receiving systemic estrogen therapy. Estrogen alone can stimulate the endometrium, increasing the risk of endometrial hyperplasia and endometrial cancer.
Progestin or another appropriate progestogen protects the endometrium from prolonged unopposed estrogen exposure. Women who have had a total hysterectomy may not require progestogen, although treatment depends on their individual clinical circumstances.
Hormone therapy requires careful risk assessment. Significant contraindications to systemic hormone therapy may include:
Unexplained vaginal bleeding.
Known or suspected estrogen-dependent malignancy.
Active or previous venous thromboembolism, depending on the clinical circumstances.
History of stroke or myocardial infarction.
Significant liver disease.
Known allergy to the medication or its ingredients.
A history of deep vein thrombosis (DVT) requires careful evaluation before considering hormone therapy. The route of administration may influence risk, but a history of thrombosis should not be managed through self-selection of hormones.
For patients who are not appropriate candidates for systemic hormone therapy, nonhormonal treatment options may provide symptom relief. Any new postmenopausal vaginal bleeding requires clinical evaluation rather than automatic treatment with hormones.
Some women prefer to avoid hormone therapy, while others have medical conditions that make systemic hormones unsuitable. Several nonhormonal medications may help reduce hot flashes and night sweats.
Common prescription options include:
Paroxetine, a selective serotonin reuptake inhibitor (SSRI).
Venlafaxine (Effexor), a serotonin-norepinephrine reuptake inhibitor (SNRI).
Certain other SSRIs or SNRIs, depending on the patient’s needs.
Gabapentin, which may be particularly useful when nighttime symptoms interfere with sleep.
Fezolinetant, a nonhormonal neurokinin 3 receptor antagonist approved for vasomotor symptoms.
Clonidine has historically been used for hot flashes, but it is generally less effective and less well tolerated than several other options. Adverse effects may include dizziness, dry mouth, constipation, and hypotension.
Advanced practice nurses should assess medication interactions, contraindications, blood pressure, symptom severity, and patient preferences when recommending treatment.
Genitourinary syndrome of menopause, or GSM, describes symptoms caused by estrogen deficiency affecting the vulva, vagina, urethra, and lower urinary tract. The condition was previously referred to as vaginal atrophy or atrophic vaginitis.
As estrogen levels decline, the vaginal tissues become thinner, less elastic, and less lubricated. These changes may cause discomfort during intercourse, irritation, urinary symptoms, and changes in vaginal pH.
Patients with genitourinary syndrome of menopause may report:
Vaginal dryness.
Vaginal burning or irritation.
Dyspareunia, or painful intercourse.
Vulvar discomfort.
Reduced vaginal lubrication.
Urinary urgency, frequency, or dysuria.
Recurrent urinary tract infections in some patients.
A vaginal pH above 5 is a commonly tested finding associated with estrogen deficiency, although pH alone does not establish the diagnosis. A complete assessment should consider symptoms, examination findings, infection, and other possible causes.
Low-dose vaginal estrogen is an effective treatment for many patients with GSM. It can improve vaginal lubrication, tissue health, and comfort during intercourse. It may also reduce some urinary symptoms and the risk of recurrent urinary tract infections in appropriate patients.
Available local treatments include vaginal creams, tablets, inserts, and rings. Treatment selection depends on symptom location, patient preference, and clinical assessment.
Women who use systemic hormone therapy but continue to experience localized vaginal or urinary symptoms may benefit from additional local treatment after discussion with their healthcare provider.
Estrogen contributes to the maintenance of bone density by helping regulate bone remodeling. After menopause, declining estrogen levels accelerate bone loss and increase the risk of osteoporosis and fragility fractures.
Osteoporosis is a skeletal disorder characterized by reduced bone strength and increased fracture risk. The hip, spine, and wrist are common fracture sites.
Several medications are used to reduce fracture risk in patients with osteoporosis or high fracture risk.
Alendronate (Fosamax) is a bisphosphonate that reduces bone resorption. It is commonly prescribed as a weekly oral medication. Patients should follow administration instructions carefully to reduce gastrointestinal irritation and improve absorption.
Raloxifene is a selective estrogen receptor modulator (SERM). It helps maintain bone density and may reduce the risk of certain invasive breast cancers in selected postmenopausal women. However, it is not appropriate for everyone and may increase the risk of venous thromboembolism.
Other evidence-based treatments include additional bisphosphonates, denosumab, and anabolic or bone-forming medications for selected patients.
Medication is only one part of osteoporosis management. Nurses should educate patients about:
Adequate calcium intake through food and supplements when appropriate.
Vitamin D adequacy.
Weight-bearing and muscle-strengthening exercise.
Smoking cessation.
Limiting excessive alcohol consumption.
Fall prevention and home safety.
Bone mineral density testing when indicated.
A patient’s fracture risk, kidney function, age, and other health conditions should guide treatment decisions.
Amenorrhea refers to the absence of menstrual periods. It is classified as primary or secondary and may result from pregnancy, hormonal disorders, anatomical abnormalities, nutritional factors, excessive exercise, or other medical conditions.
Primary amenorrhea refers to the absence of menarche by the expected age. Common clinical definitions include:
No menarche by age 15.
No menarche within three years after the onset of breast development.
No breast development by age 13, which warrants evaluation for delayed puberty.
Primary amenorrhea requires assessment of pubertal development, family history, growth, reproductive anatomy, and possible endocrine causes.
Secondary amenorrhea is the absence of menstruation in an individual who previously menstruated. Common diagnostic thresholds are:
No menstrual period for three months in someone with previously regular cycles.
No menstrual period for six months in someone with previously irregular cycles.
Pregnancy should be excluded first in anyone who could be pregnant. Additional evaluation may include thyroid-stimulating hormone, prolactin, gonadotropins, estradiol, and pelvic ultrasound, depending on the history and physical examination.
Possible causes include polycystic ovary syndrome, hypothalamic dysfunction, hyperprolactinemia, thyroid disease, premature ovarian insufficiency, and structural abnormalities.
Dysmenorrhea is pelvic pain associated with menstruation. It is a common gynecologic complaint and may be classified as primary or secondary.
Primary dysmenorrhea typically results from increased prostaglandin activity, which causes uterine contractions and menstrual cramping. Secondary dysmenorrhea occurs when an underlying pelvic condition causes the pain.
First-line treatment for primary dysmenorrhea often includes nonsteroidal anti-inflammatory drugs (NSAIDs). These medications reduce prostaglandin production and may improve menstrual pain when started before or at the onset of menstruation.
Additional management strategies include:
Applying a heating pad or other heat therapy.
Regular physical activity.
Adequate sleep and stress management.
Hormonal contraceptives when clinically appropriate.
Evaluation for underlying conditions when symptoms are persistent or severe.
Severe pain, progressive symptoms, abnormal bleeding, infertility, or pain that does not respond to treatment may suggest secondary dysmenorrhea. Possible causes include endometriosis, adenomyosis, uterine fibroids, or pelvic inflammatory disease.
Infertility evaluation aims to identify factors that may interfere with conception. Assessment should consider both partners because infertility may involve ovulatory, tubal, uterine, cervical, or male-factor causes.
For women younger than 35 years, evaluation is generally recommended after 12 months of regular unprotected intercourse without conception. For women aged 35 years or older, evaluation is generally recommended after six months. Earlier evaluation may be appropriate when there are risk factors such as irregular menstruation, suspected endometriosis, tubal disease, or known fertility concerns.
Evaluation may include a detailed menstrual history, ovulation assessment, pelvic examination, and imaging.
Transvaginal ultrasound can help assess:
Ovarian anatomy.
Follicular development.
Uterine structure.
Endometrial appearance.
Fibroids, ovarian cysts, or other structural abnormalities.
Ovulation testing may include urinary luteinizing hormone kits or serum progesterone testing at an appropriate time in the cycle. The timing of testing should be individualized according to cycle length and suspected ovulation.
A hysterosalpingogram is an imaging procedure used to evaluate the uterine cavity and determine whether the fallopian tubes are open. Contrast material is introduced through the cervix while X-ray imaging is performed.
HSG is commonly scheduled after menstruation and before ovulation, often during the first half of the menstrual cycle. The exact timing depends on cycle length, pregnancy exclusion, and local protocol.
HSG may identify:
Blocked or patent fallopian tubes.
Abnormalities of the uterine cavity.
Certain structural conditions affecting fertility.
Laparoscopy is a minimally invasive surgical procedure that may be used when there is suspected endometriosis, pelvic adhesions, or other pelvic pathology. It is not routinely required for every infertility evaluation.
Additional testing may include semen analysis, ovarian reserve assessment, and targeted endocrine testing. The diagnostic plan should be guided by the patient’s history, examination, age, and clinical indications.
These important points can help nursing students prepare for NU576 Unit 3 assessments.
Perimenopause is the transition before menopause and commonly occurs during the mid-to-late 40s.
Menopause is diagnosed after 12 consecutive months without menstruation.
Pregnancy remains possible during perimenopause because ovulation may still occur.
Menstrual cycles often become irregular during the menopausal transition.
Hot flashes and night sweats are common vasomotor symptoms.
Estrogen therapy is generally combined with a progestogen in women with an intact uterus.
Unexplained postmenopausal bleeding requires evaluation.
Soy and red clover contain phytoestrogens.
Estrogen deficiency contributes to vaginal dryness, tissue thinning, and changes in vaginal pH.
Osteoporosis risk increases after menopause because of accelerated bone loss.
Alendronate is a bisphosphonate used to reduce fracture risk.
Raloxifene is a selective estrogen receptor modulator used for selected osteoporosis and breast cancer risk-reduction indications.
NSAIDs are commonly used as first-line treatment for primary dysmenorrhea.
Pregnancy testing is an essential first step in evaluating amenorrhea.
HSG evaluates the uterine cavity and fallopian tube patency.
Infertility evaluation should consider both partners.
Advanced practice nurses play an important role in educating patients about reproductive aging, evaluating menstrual concerns, and supporting evidence-based treatment decisions. Menopause symptoms should be assessed in the context of the patient’s health history, quality of life, and treatment preferences.
Nurses should also recognize that abnormal bleeding, severe pelvic pain, persistent amenorrhea, and difficulty conceiving may require further diagnostic evaluation. Individualized care, preventive counseling, and appropriate referrals help promote safe and effective gynecologic health management across the lifespan.
American College of Obstetricians and Gynecologists. (n.d.). Hormone therapy for menopause. https://www.acog.org/womens-health/faqs/hormone-therapy-for-menopause
American College of Obstetricians and Gynecologists. (n.d.). The menopause years. https://www.acog.org/womens-health
American Society for Reproductive Medicine. (2021). Fertility evaluation and treatment. https://www.asrm.org/topics/topics-index/infertility/
National Institute on Aging. (n.d.). What is menopause? National Institutes of Health. https://www.nia.nih.gov/health/menopause
National Osteoporosis Foundation. (n.d.). Osteoporosis prevention and treatment. https://www.nof.org/
The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028
World Health Organization. (2024). Osteoporosis. https://www.who.int/news-room/fact-sheets/detail/osteoporosis
